OR WAIT null SECS
August 30, 2018
The European Commission (EC) has approved GlaxoSmithKline’s (GSK) Nucala (mepolizumab) as an add-on treatment for severe refractory eosinophilic asthma in pediatric patients six to 17 years old.
August 29, 2018
Bristol-Myers Squibb appointed a new executive vice-president and chief commercial officer from within the company, effective immediately.
August 28, 2018
The European Commission (EC) has approved Novartis’ chimeric antigen receptor T cell (CAR-T) cell therapy Kymriah for the treatment of B-cell acute lymphoblastic leukemia and relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
August 27, 2018
The acquisition will support Novo Nordisk’s development of glucose-responsive insulins.
August 24, 2018
Dompé Farmaceutici’s Oxervate (cenegermin), a topical eye drop, is the first treatment approved by the agency for neurotrophic keratitis, a rare disease affecting the cornea.
August 17, 2018
The acquisition will strengthen Astellas Pharma’s position in ophthalmology.
GSK will close the Sligo, Ireland skincare product manufacturing site by 2021.
The acquisition is expected to support Emergent BioSolutions’ focus on public health threats and emerging infectious disease.
August 16, 2018
The companies entered a multi-year R&D collaboration to develop mRNA-based flu vaccines.
August 14, 2018
Pharmaceutical scientist association announces upcoming term’s board of directors.